Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Article Abstract:
A report on individuals who developed severe congestive heart failure while on imatinib mesylate (Gleevec), which is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia is presented. The data results derived from studies in cultured cardiomyocytes, mice and humans, suggest that imatinib is cardiotoxic and, in humans, could lead to severe left ventricular dysfunction and heart failure.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Antibacterial resistance worldwide: Causes, challenges and responses
Article Abstract:
The optimism of the early period of antimicrobial discovery is tempered by the emergence of bacterial strains with resistance to the therapeutics. It is showed that drug resistance presents an ever-increasing global public health threat that involves all major microbial pathogens and antimicrobial drugs.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The proteasome -- an emerging therapeutic target in cancer. Producing penicillin. The price tag on progress - chemotherapy for colorectal cancer
- Abstracts: Ethnobotanical tattoing of the gingiva: literature review and report of a case. Formation of mucogingival defects associated with intraoral and perioral piercing: case reports
- Abstracts: Efficacy of thermal balloon ablation in patients with abnormal uterine bleeding. Use of health services associated with increased menstrual loss in the United States
- Abstracts: Regionalization of high-risk surgery and implications for patient travel times. Disparities in the utilization of high-volume hospitals for complex surgery
- Abstracts: Planning to improve the hospital experience for older inpatients